Oct 25, 2024
PreDx at CTAD Madrid: New cell model to predict CAA and ARIA
Pre Diagnostics presents the poster “PreDXClearance, exploring new biomarkers to predict ARIA/CAA and personalize therapy in AD” at the Clinical Trial in Alzheimers Disease (CTAD) in Madrid. Emerging AD immunotherapies using Aβ-specific antibodies offer hope by potentially halting AD progression. However, up to 40% of patients experience adverse effects linked to cerebral amyloid angiopathy (CAA), known as Amyloid-Related Imaging Abnormalities (ARIA). ARIA presents as brain swelling, sometimes progressing to bleeding, causing lasting damage and, in severe cases, becomes life-threatening. Successful clinical implementation of these drugs requires early AD detection and complementary diagnostics for assessing ARIA/CAA risk.
In this study, we provide the first evidence of the potential for this novel tool to predict the risk of ARIA with an in-vitro and non-invasive test. This will lead to more effective, accessible, and safer treatments for AD patients.
